# The Role of Dexmedetomidine as Myocardial Protector in Pediatric Cardiac Surgery Total Correction of Tetralogy of Fallot

> **NCT05579964** · PHASE2,PHASE3 · COMPLETED · sponsor: **National Cardiovascular Center Harapan Kita Hospital Indonesia** · enrollment: 66 (actual)

## Conditions studied

- Congenital Heart Disease in Children
- Cardiopulmonary Bypass
- Tetralogy of Fallot

## Interventions

- **DRUG:** Dexmedetomidine Hcl 100 Mcg/mL Inj
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05579964
- **Lead sponsor:** National Cardiovascular Center Harapan Kita Hospital Indonesia
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-10
- **Primary completion:** 2023-04-10
- **Final completion:** 2023-06-10
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2023-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05579964

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05579964, "The Role of Dexmedetomidine as Myocardial Protector in Pediatric Cardiac Surgery Total Correction of Tetralogy of Fallot". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05579964. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*